Kymera Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, rising from 88 to 92.
How To Use Stock Charts To Stay Profitable And Protected
IBD's unique RS Rating tracks market leadership by using a 1 (worst) to 99 (best) score that identifies how a stock's price action over the last 52 weeks matches up against the rest of the market.
Decades of market research shows that the stocks that go on to make the biggest gains typically have an RS Rating north of 80 as they begin their largest climbs.
Is Kymera Therapeutics Stock A Buy?
Kymera Therapeutics stock recently reclaimed its 200-day moving average and is not in a proper buying range. See if the biotech stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.
The clinical-stage biotech firm posted 0% EPS growth in its most recent report, while sales growth came in at 115%.
Kymera Therapeutics stock earns the No. 109 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, Catalyst Pharmaceuticals and ADMA Biologics are among the top 5 highly rated stocks within the group. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
